INNA-051
Vaccine candidate against COVID-19
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Viral vector |
Clinical data | |
Routes of
administration |
Intranasal |
INNA-051 is a COVID-19 vaccine candidate developed by Ena Respiratory. [1] [2]
References
- ↑ "INNA-051 intranasal safety and tolerability study" . anzctr.org.au . 21 April 2021. ACTRN12621000607875p . Retrieved 20 May 2021 .
- ↑ Clinical trial number NCT05118763 for "Intranasal INNA-051 for Prevention of COVID-19 in Adults" at ClinicalTrials.gov
Scholia
has a profile for
INNA-051
(Q110269792)
.
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
|
||||||||||
Inventors/
researchers |
|||||||||||
Controversy | |||||||||||
Related | |||||||||||
|
This article about COVID-19 vaccines is a stub . You can help Wikipedia by expanding it . |
This article about vaccines or vaccination is a stub . You can help Wikipedia by expanding it . |